Cardiovascular disease (CVD) is the leading cause of death worldwide, resulting in over 17 million deaths annually. According to the CDC, one-third of all U.S. deaths are caused by heart disease, stroke, or other cardiovascular diseases.
Meridian is conducting a phase 3 clinical research study for an investigational medication looking to reduce the risk of heart attack or stroke in those with cardiovascular disease.
- Must be age 40 or older
- Must be diagnosed with cardiovascular disease
- Must be on a stable and high-intensity lipid-lowering regimen consisting of a statin medication, such as atorvastatin or rosuvastatin (participants using a different high-intensity statin must be able to switch to atorvastatin or rosuvastatin to be eligible)
- May receive reimbursement for travel and expenses
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can talk to a Meridian enrollment specialist about this study by calling (912) 623-2240 (New York) or (402) 934-7563 (Cincinnati).
Submit your information
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.